Amneal Pharma: Insider Sell‑Offs, Stock Price Dip, & New Biosimilar Growth Plan
Amneal Pharmaceuticals shares see $6.3M insider sell‑off, yet new Genpharmasec partnership and biosimilar deal promise growth potential.
2 minutes to read
AMNEAL PHARMACEUTICALS INC
Amneal Expands as Biosimilar Leader with Kashiv Acquisition, Strong Q1 Results and Promising Parkinson’s Data
Amneal Pharmaceuticals accelerates growth with Kashiv BioSciences acquisition, strong Q1 results, and positive Phase 4 data for Parkinson’s drug CREXONT.
4 minutes to read
Amneal Pharmaceuticals Strengthens Balance Sheet with Strategic Refinancing and Growth Initiatives
Amneal Pharmaceuticals Inc has made strategic financial moves to strengthen its balance sheet and support future growth, including a proposed refinancing of its credit agreement and a 3% revenue growth in Q2.
3 minutes to read
Amneal Pharmaceuticals Reports Strong Q1 2025 Performance Amid Strategic Shift
Amneal Pharmaceuticals Inc. reports strong Q1 2025 performance, with 5% revenue growth and 50% EPS increase, driven by strategic initiatives and focus on high-growth therapeutic areas.
2 minutes to read